_Where is the $10 billion ?
[ ACT UP/Paris Press Release ]
One year after the touted announcement by the G8 of the creation of the Global Fund, the contribution by rich countries, among which most EU Members, is not 10% of original targets. Where is the promised $10 billion ? The Global Fund's coffers have been almost emptied by its first disbursement round.
European Union : Where is the $10 Billion ?
10 July 2002 ..In the 12 months since the Genoa summit, 3 million people have died of AIDS. By 2015 if the trend is not reversed, 100 million people will be infected with HIV, 95 million of them condemned to death in the absence of treatment.
This doomsday scenario can be avoided : today we know how to fight the epidemic ; we know that HIV-infected people in developing countries are not doomed, but can be kept alive ; we know what treatments to implement. What's required now is adequate resources in the amount of 10 billion dollars a year globally. The time has come for Europe to pay its share of this global effort : 4 billion euros per year.
Further, the EU must cease to hinder export generic versions between Southern countries. At the Doha summit, last November, WTO members finally recognized the primacy of patient rights over patent rights, and the possibility for countries to import or make generic versions of patented drugs. But now the EU is doing a U-turn on its Doha commitments, with its current WTO position seeking to block poor countries from actually importing generics by limiting possibilities to export the drugs.
The EU, as the world's second economic and political power, shares responsibility for the 22 million deaths claimed by aids to this day and the 10,000 more daily deaths accruing to its toll. It shares responsibility for the uninterrupted spread of a disease that now threatens the world's stability and the very survival of entire continents.
The EU must immediately :
Pay its share of
the $10 billion global war effort
Ensure as quickly as possible the free exportation of affordable generic medicines from manufacturing countries to countries which are not producing drugs, in order to respect WTO commitments in Doha.
Contact : Gaëlle Krikorian email@example.com
European Commission ACT UP Action
USAIDS Action > ---
[ ACT UP/Paris Press Kit ]
Where is the 10 billion dollars
Almost 10 000 people die of AIDS every day.
Today we know how to fight the epidemic ; we know that HIV-infected people in developing countries are not doomed, but can be kept alive ; we know what treatments to implement.
And yet, the epidemic keeps spreading ; every year millions of people are infected and die.
There is only one explanation for this state of things : world leaders refuse to invest the necessary funds.
One year ago the G8 countries and the Member States of the United Nations acknowledged it was necessary to spend a minimum of ten billions dollars a year to fight AIDS and committed themselves to providing this amount.
Today one question on everyone's mind is : where is the 10 billion dollars ?
There are solutions.
When multitherapies were launched six years ago and sick people asked for access to antiretrovials everywhere in the world, the reaction of donors was the same : they were unanimous in rejecting such a request which they considered unacceptable, utopian and demagogic.
Throughout the years we removed obstacles one after the other :
It is now at last recognized that an efficient policy to fight the epidemic combines treatment and prevention, and that excluding one of these two components for economic reasons turns out to be a disaster not only in terms of public health, but also in terms of economic development.
The opinion that only prevention measures could stem the epidemic prevailed for twenty years : it led to the infection and deaths of millions of people. Experts are absolutely sure : an efficient form of prevention requires people becoming aware of the disease and therefore getting medical care. Right now only antiretrovirals fight the virus and keep people alive ; they fundamentally change our approach to the disease.
But twenty years of self-deception and miserliness have elapsed with millions of people dying and the epidemic relentlessly spreading in size and scope, before the wisdom of worn-out clichés which determined our way of thinking and acting, was challenged.
NGOs and HIV researchers have proved access to antiretroviral treatments is feasible in resource-poor countries.
Medical care with antiretrovials is possible ; molecules are naturally just as effective for people in developing countries as for people in developed countries ; the patients who are being treated with antiretrovirals perfectly comply with the treatment regimens if they understand their future is at stake.
Since multitherapies were launched, international donors have been claiming that the cost of such medicines is too high for them to pay for the medical care of people living with HIV/AIDS in poor countries.
For two years, however, generic copies of particularly expensive antiretrovirals have been produced in developing countries by public institutions (Brazil, Thailand) or private companies (India) and sold at much lower prices than those of brand-name drugs by patent holders.
In October 2000 an Indian producer launched a generic tritherapy for $ 800 a year, which represented a saving of more than 90% in comparison with the prices of multinational corporations. In February 2001 his price dropped to $350. In October 2001 the price of another producer came down to $295. Right now the lowest prices are close to $200.
The marketing of these low-cost generic drugs immediately resulted in Big Pharma adjusting its own prices despite the fact that until then it had adamently refused to accede to the entreaties of UN agencies and grant significant price reductions to developing countries.
Thus the marketing of generic antiretrovials has proved two things :
that medicines can be sold at prices much lower than those of western pharmaceutical companies( we do not know the marginal costs of production yet, but they must undoubtedly be lower than the prices of generic producers)
that generic competition is the most efficient means to get a drastic and lasting reduction in the prices of medicines. Such competition is much more persuasive and efficient than occasional charitable donations by patent holders enjoying a monopoly situation.
Last december, during the Internationale Conference of WTO in Doha, the 142 Member States signed on a declaration recognizing the right for the countries to produce and import low cost generic drugs. Now all patients should have access to these medications ; countries should be able to buy large quantities of generics.
The G8 countries must immediately commit to devoting O.O5%
at least of their GNP to the funding of the fight against AIDS.
The WHO must be the spearhead of the
promotion campaign of anti-AIDS generic medicines :
For medicines to become affordable, several measures have to be taken :
- Developing bulk procurement at the international as well as the regional level in order to be able to negotiate better prices on the basis of bulk purchasing of medicines ;
- Increasing production capacity and transfer of technology to encourage local production in developing countries ;
- Issuing compulsory licences to make it possible to produce and import generic medicines ;
- Resorting to parallel importation ;
- And generally speaking, encouraging systematic competition between brand-name and generic medicines.
Access to generics is of fundamental importance for developing countries and the only long-term prospect of having access to the widest range of treatments at the lowest prices.
The WHO must not embroil developing countries in partnerships with private companies, such as Accelerating access, without guaranteeing the negotiation framework is transparent, ethical principles are respected and some results are achieved. The WHO must urgently review its policy and develop a strategy based above all on competition among producers.
The WHO must be able to provide countries with the most exhaustive information possible on suppliers of anti-AIDS medicines as well as their prices, and necessarily include generics producers.
The WHO must speed up the process of endorsing generic medicines to ease access to them in developing countries.
The WHO must provide developing countries with expertise and technical support to help them devise their legislation on intellectual property, incorporating the flexible provisions of the TRIPS Agreement and the Doha Declaration to have access to generics.
The WHO must support countries trying to develop bulk procurement of medicines at the best prices possible as well as local production and tranfer of technology.
The WHO must provide developing countries
wishing to set up national access programs for antiretroviral
treatment with genuinely adequate technical aid.
Today the key issue is to rapidly scale up access to medicines in developing countries, to increase the number of health care centers and make it possible for many more people to have access to treatments in the countries where only a few hundred people are being treated.
World leaders are responsible for the disaster
Since the prices of medicines can be significantly reduced, nothing should prevent rich countries from undertaking to fund bulk purchasing of treatments and the strengthening of health care structures in order to widen access to medicines for people with AIDS in poor countries.
Yet, the necessary funds are not available.
In april 2001 at the African Summit on HIV/AIDS, tuberculosis and other infectious diseases in Abuja, Kofi Annan announced the creation of a Global Fund with an annual commitment of 10 billion dollars to fight AIDS, and declared : « It is unacceptable that the poorest sick people cannot have access to medicines that have changed the lives of sick people in rich countries. »
One year later, despite the pledges of the Member States of the United Nations in June 2001 and of the G8 countries in July 2001, the proposed 2002 funding does not reach 2.08 billion dollars and the funds disbursed this year will reach only 700 to 800 million dollars.
At UNGASS last June in New York and then at the Genoa meeting of the G8 heads of state in July, developed countries committed themselves to funding the Glabal Fund.
Sick people in developing countries, NGOs and activists may have believed then that the Global Fund was going to be a major turning point in the fight against the epidemic : to enable at last to scale up funding and treatment programs.
However, the present funding commitment shows that international donors and political leaders hedge pledges to fight AIDS. Moreover, they are still reluctant to fund medicines. Thus, Richard Feachem, the executive director of the Global Fund,is unaware of or denies the real situation, the vast needs of people living with HIV/AIDS in developing countries, and refuses to consider purchases of antiretroviral medications a priority. Thus if the epidemic keeps killing millions of sick people every year, if millions of people get infected every year, it is above all because international donors refuse to invest the necessary funds to stop the scourge.
Today in Barcelona, the question which is raised and remains unanswered is : where is the ten billion dollars ?
AIDS and G8 :
Where is the 10 billion dollars ?
A year after the Group of Eight Industrialized Countries announced the "historic" creation of a Global Fund to fight AIDS, the contribution of the richest countries does not reach one tenth of the goal set forth by Annan.
Where is the ten billion dollars ? There is almost no money left in the coffers of the Fund. In the past 12 months almost 3 million people have died of AIDS and the epidemic continues expanding in size and scope.
In 2000 and more than 15 years after the beginning of the epidemic, the UN Security Council followed by the US Security Council announced that the AIDS pandemic was one of the most serious threats to world stability.
A few months later the World Bank warned the international community that the devastating effects of the epidemic in poor countries were about to annihilate 50 years of development. Then Jeffrey Sachs, the head of the Harvard Institute in charge of the Health and Macroeconomic Commission of the WHO, published an expert report estimating the funds necessary to control the pandemic at 10 billion dollars a year ú a mere 0.05% of the GNP of the 8 richest countries, and less than what the G8 countries keep collecting from poor countries as debt service.
In April 2001 at the Abuja Summit in Nigeria, Kofi Annan, the UN Secretary General, called for an international financial mobilisation "without any common measure with the resources we presently spend if we want to win the war against AIDS". The UN General Assembly Special Session on HIV/AIDS adopted the same target of 10 billion dollars a year. Thus in July 2001, in Genoa, the 8 richest states announced the creation of a Global Fund to finance the global war on aids.
To date their contributions do not add up to 500 million dollars a year, that is less than 5% of the target. Where is the 10 billion dollars ? In the last 12 months almost 3 million people have died of AIDS. By 2015, if the trend is not reversed, 100 million people will be infected with HIV/AIDS and 95 million will eventually die.
Throughout the years, grass-roots activists, people with HIV, NGOs and doctors have mobilised day after day to fight the epidemic and save infected people. However, without more funds they will lose the fight.
The G8 industrialized countries bear responsibility for the deaths of 10,000 persons every day ; responsibility for the continuous expansion of the epidemic which threatens the development and stability of entire continents.
This is why the G8 countries must immediately commit to devoting O.O5% at least of their GNP to the funding of the fight against AIDS.
WHERE IS THE 10 BILLION DOLLARS??
One year after the touted announcement by the G8 of the creation of the Global Fund, the contribution by rich countries is not 10% of original targets. Where is the promised 10 billion? The Global Fund's coffers have been almost emptied by its first disbursement round. In the 12 months since the Genoa summit, 3 million people have died of AIDS. by 2015 if the trend is not reversed, 100 million people will be infected with HIV, 95 million of them condemned to death in the absence of treatment.
This doomsday scenario can be avoided: we simply have to scale up the various interventions (HAART, psychosocial support, prevention campaigns, etc) that the last 3 International AIDS Conferences have shown are effective against the epidemic. What's required now is adequate resources, in the amount of 10 Billion dollars a year at the global level. The time has come for each rich country to pay its share of the global war effort to turn back AIDS.
Rich countries, as economic and political leaders of this world, bear responsibility for the 22 million deaths claimed by AIDS to this day and the 10,000 more daily deaths accruing to its toll. They bear responsibility for the uninterrupted spread of a disease that has now come to threaten the world's stability and the very survival of entire continents. Rich countries must immediately pay the additional $10 Billion needed for the global war against AIDS, in the amount of:
USA : $4 Billion
Japan : $1.5 Billion
Germany, UK, France, Italy : $1 Billion each
Canada : $300 Million
Spain : $200 Million
Agence France Presse
July 10, 2002
Protests mark AIDS conference for third day running
Protestors disrupted the world AIDS forum here Wednesday for the third day running, trashing the European Commission's exhibition stand, occupying two others and staging a rowdy demonstration against Coca-Cola Corp.
About a dozen militants from AIDS advocacy groups led by ACT UP, blowing shrilly on plastic whistles, overran the European Commission booth, tearing up pamphlets and plastering its walls with orange protest stickers.
The Commission's personnel left the stand, and cleaners were brought in to clear up the mess.
A noisy protest unfolded at a stand operated by the Catalonian government and at another run by GlaxoSmithKline, a leading manufacturer of HIV drugs, while Brazilian militants staged a noisy protest outside a Brazilian AIDS stand. In the centre of the sprawling venue where the 14th International AIDS Conference is unfolding, protestors in front of a giant inflatable bottle of Coca-Cola accused the drinks company and the London-based mining corporation Anglo American of refusing to provide treatment to workers with HIV in poor countries.
On Tuesday, protestors jeered US Secretary of Health Tommy Thompson and French Health Minister Jean-Francois Mattei, and on Monday, they briefly occupied the stand of the Roche drug company.
Protests by ACT UP and other US and European groups have become a familiar feature of world AIDS conferences, and are usually small, noisy but otherwise peaceful affairs.
AIDS activists are demanding that rich countries kick in more money to help prevention and treatment in poorer countries and that pharmaceutical giants provide anti-retroviral drugs, or generic copies of them, for free.
But they also have a list of grievances about public health policy in their home countries.
The demonstrations are seen in some quarters as a useful way to pressure rich governments.
Others, though, fear they exacerbate northern-hemisphere issues, sapping interest in the needs of the southern hemisphere, which is bearing the brunt of the global pandemic.
The conference, which opened in Barcelona on Sunday, runs until Friday, gathering 15,000 doctors, researchers, policy-makers and grass-roots workers.
see also: Secretary Thompson to People with AIDS: Drop Dead
LETTERS TO THE EDITOR: Europe needs to spend
on drugs for the poor
By Dorette Corbey ~ Financial Times ~ July 08, 2002
From Dr Dorette Corbey MEP.
Sir, The international community gathers in Barcelona this week to discuss how to fight the global Aids epidemic. Conferences such as these painfully reveal that poor countries largely depend on policies made in the European Union and other wealthy places for access to essential medicines. Combating severe health crises in less developed countries will require public leadership.
Although the European Commission is investing more into global Aids treatment, the amount is largely insufficient to meet the $8bn that Kofi Annan, the UN secretary-general, says is needed to fight Aids effectively.
But the Commission should not only invest more in treatment of patients with currently available medicines; it should also develop an entirely new, needs-based research and development strategy. The market has clearly failed to develop effective, easy-to-use and inexpensive drugs to prevent or cure poverty-related diseases such as Aids, malaria, TB and leishmaniasis. Therefore the EC should show commitment by collaborating with the best experts from around the world, including the pharmaceuticals industry, to develop the medicines that are needed so badly in developing countries.
Pharmaceuticals markets are highly profitable but profits will not cure the 60m patients now infected with HIV/Aids. Meanwhile, expenditures on medicines are rising within the EU - despite the lack of real innovation. Prices vary from country to country and are still a result of national negotiations. Joint consultations at a European level will bring public authorities into the position to encourage the industry to invest in neglected diseases in poor countries or negotiate research and development priorities.
If it only had the commitment to show public leadership and the willingness seriously to invest in developing badly needed drugs, the Commission could lead in the fight against the worst global epidemic since the Spanish Plague. We do have the money in Europe; we just need to spend it right (and start spending it now).
Dorette Corbey, European Parliament, Brussels, Belgium
use back button on browser to return
back to> Barcelona AIDS Conference Reports > > >